BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that Oncaspar-IV™, the next generation pegylated L-asparaginase, received approval from the Commission of the European Communities for designation as an orphan medicinal product.
